Mild Cognitive Impairment: Ten Years Later | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Petersen  RCDoody  RKurz  A  et al.  Current concepts in mild cognitive impairment.  Arch Neurol 2001;58 (12) 1985- 1992PubMedGoogle ScholarCrossref
2.
Molano  JBoeve  BFerman  T  et al.  Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study [published online ahead of print November 4, 2009].  Brain PubMedGoogle Scholar
3.
Petersen  RCSmith  GEWaring  SCIvnik  RJTangalos  EGKokmen  E Mild cognitive impairment: clinical characterization and outcome.  Arch Neurol 1999;56 (3) 303- 308PubMedGoogle ScholarCrossref
4.
Petersen  RC Conceptual overview. Petersen  RC Mild Cognitive Impairment Aging to Alzheimer's Disease New York, NY Oxford University Press2003;1- 14Google Scholar
5.
Gauthier  SReisberg  BZaudig  M  et al. International Psychogeriatric Association Expert Conference on mild cognitive impairment, Mild cognitive impairment.  Lancet 2006;367 (9518) 1262- 1270PubMedGoogle ScholarCrossref
6.
Reisberg  BFerris  Sde Leon  MJ  et al.  Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type.  Drug Dev Res 1988;15 (2-3) 101- 114Google ScholarCrossref
7.
Morris  JC The Clinical Dementia Rating (CDR): current version and scoring rules.  Neurology 1993;43 (11) 2412- 2414PubMedGoogle ScholarCrossref
8.
Visser  PJScheltens  PVerhey  FR  et al.  Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.  J Neurol 1999;246 (6) 477- 485PubMedGoogle ScholarCrossref
9.
Winblad  BPalmer  KKivipelto  M  et al.  Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.  J Intern Med 2004;256 (3) 240- 246PubMedGoogle ScholarCrossref
10.
Petersen  RC Mild cognitive impairment as a diagnostic entity.  J Intern Med 2004;256 (3) 183- 194PubMedGoogle ScholarCrossref
11.
Petersen  RCAisen  PSBeckett  LA  et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.  Neurology Google Scholar
12.
Busse  AHensel  AGuhne  UAngermeyer  MCRiedel-Heller  SG Mild cognitive impairment: long-term course of four clinical subtypes.  Neurology 2006;67 (12) 2176- 2185PubMedGoogle ScholarCrossref
13.
Ganguli  MDodge  HHShen  CDeKosky  ST Mild cognitive impairment, amnestic type: an epidemiologic study.  Neurology 2004;63 (1) 115- 121PubMedGoogle ScholarCrossref
14.
Larrieu  SLetenneur  LOrgogozo  JM  et al.  Incidence and outcome of mild cognitive impairment in a population-based prospective cohort.  Neurology 2002;59 (10) 1594- 1599PubMedGoogle ScholarCrossref
15.
DeCarli  C Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment.  Lancet Neurol 2003;2 (1) 15- 21PubMedGoogle ScholarCrossref
16.
Ritchie  KArtero  STouchon  J Classification criteria for mild cognitive impairment: a population-based validation study.  Neurology 2001;56 (1) 37- 42PubMedGoogle ScholarCrossref
17.
Lopez  OLJagust  WJDeKosky  ST  et al.  Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1.  Arch Neurol 2003;60 (10) 1385- 1389PubMedGoogle ScholarCrossref
18.
Roberts  ROGeda  YEKnopman  D  et al.  The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.  Neuroepidemiology 2008;30 (1) 58- 69PubMedGoogle ScholarCrossref
19.
Unverzagt  FWGao  SBaiyewu  O  et al.  Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging.  Neurology 2001;57 (9) 1655- 1662PubMedGoogle ScholarCrossref
20.
Hänninen  THallikainen  MTuomainen  SVanhanen  MSoininen  H Prevalence of mild cognitive impairment: a population-based study in elderly subjects.  Acta Neurol Scand 2002;106 (3) 148- 154PubMedGoogle ScholarCrossref
21.
Palmer  KBäckman  LWinglad  BFratiglioni  L Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease.  Am J Geriatr Psychiatry 2008;16 (7) 603- 611PubMedGoogle ScholarCrossref
22.
Das  SKBose  PBiswas  A  et al.  An epidemiologic study of mild cognitive impairment in Kolkata, India.  Neurology 2007;68 (23) 2019- 2026PubMedGoogle ScholarCrossref
23.
Di Carlo  ALamassa  MBaldereschi  M  et al.  CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia.  Neurology 2007;68 (22) 1909- 1916PubMedGoogle ScholarCrossref
24.
Fischer  PJungwirth  SZehetmayer  S  et al.  Conversion from subtypes of mild cognitive impairment to Alzheimer dementia.  Neurology 2007;68 (4) 288- 291PubMedGoogle ScholarCrossref
25.
Manly  JJTang  MXSchupf  NStern  YVonsattel  JPMayeux  R Frequency and course of mild cognitive impairment in a multiethnic community.  Ann Neurol 2008;63 (4) 494- 506PubMedGoogle ScholarCrossref
26.
Plassman  BLLanga  KMFisher  GG  et al.  Prevalence of cognitive impairment without dementia in the United States.  Ann Intern Med 2008;148 (6) 427- 434PubMedGoogle ScholarCrossref
27.
Roberts  ROGeda  YEKnopman  DS  et al.  Men are more likely to have mild cognitive impairment than women: the Mayo Clinic Study of Aging [abstract].  Neurology 2008;70 (11) ((suppl 1)) A225Google Scholar
28.
Farias  STMungas  DReed  BRHarvey  DDeCarli  C Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.  Arch Neurol 2009;66 (9) 1151- 1157PubMedGoogle ScholarCrossref
29.
Petersen  RCThomas  RGGrundman  M  et al. Alzheimer's Disease Cooperative Study Group, Vitamin E and donepezil for the treatment of mild cognitive impairment.  N Engl J Med 2005;352 (23) 2379- 2388PubMedGoogle ScholarCrossref
30.
Solfrizzi  VPanza  FColacicco  AM  et al. Italian Longitudinal Study on Aging Working Group, Vascular risk factors, incidence of MCI, and rates of progression to dementia.  Neurology 2004;63 (10) 1882- 1891PubMedGoogle ScholarCrossref
31.
Tschanz  JTWelsh-Bohmer  KALyketsos  CG  et al. Cache County Investigators, Conversion to dementia from mild cognitive disorder: the Cache County Study.  Neurology 2006;67 (2) 229- 234PubMedGoogle ScholarCrossref
32.
Ravaglia  GForti  PMontesi  F  et al.  Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population [published online ahead of print November 20, 2007].  J Am Geriatr Soc 2008;56 (1) 51- 58PubMedGoogle ScholarCrossref
33.
Petersen  RCSmith  GEIvnik  RJ  et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.  JAMA 1995;273 (16) 1274- 1278PubMedGoogle ScholarCrossref
34.
Aggarwal  NTWilson  RSBeck  TLBienias  JLBerry-Kravis  EBennett  DA The apolipoprotein E ε4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.  Neurocase 2005;11 (1) 3- 7PubMedGoogle ScholarCrossref
35.
Corder  EHSaunders  AMStrittmatter  WJ  et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.  Science 1993;261 (5123) 921- 923PubMedGoogle ScholarCrossref
36.
Killiany  RJGomez-Isla  TMoss  M  et al.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.  Ann Neurol 2000;47 (4) 430- 439PubMedGoogle ScholarCrossref
37.
Jack  CR  JrPetersen  RCXu  YC  et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.  Neurology 1999;52 (7) 1397- 1403PubMedGoogle ScholarCrossref
38.
Fox  NCScahill  RICrum  WRRossor  MN Correlation between rates of brain atrophy and cognitive decline in AD.  Neurology 1999;52 (8) 1687- 1689PubMedGoogle ScholarCrossref
39.
Jack  CR  JrSlomkowski  MGracon  S  et al.  MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.  Neurology 2003;60 (2) 253- 260PubMedGoogle ScholarCrossref
40.
Kantarci  KWeigand  SDPetersen  RC  et al.  Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease.  Neurobiol Aging 2007;28 (9) 1330- 1339PubMedGoogle ScholarCrossref
41.
Jagust  WJLandau  SMShaw  LM  et al.  Relationships between biomarkers in aging and dementia.  Neurology 2009;73 (15) 1193- 1199PubMedGoogle ScholarCrossref
42.
Shaw  LMKorecka  MClark  CMLee  VMTrojanowski  JQ Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.  Nat Rev Drug Discov 2007;6 (4) 295- 303PubMedGoogle ScholarCrossref
43.
Hansson  OZetterberg  HBuchhave  PLondos  EBlennow  KMinthon  L Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.  Lancet Neurol 2006;5 (3) 228- 234PubMedGoogle ScholarCrossref
44.
Mattsson  NZetterberg  HHansson  O  et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.  JAMA 2009;302 (4) 385- 393PubMedGoogle ScholarCrossref
45.
Shaw  LMVanderstichele  HKnapik-Czajka  M  et al. Alzheimer's Disease Neuroimaging Initiative, Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.  Ann Neurol 2009;65 (4) 403- 413PubMedGoogle ScholarCrossref
46.
Klunk  WEEngler  HNordberg  A  et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.  Ann Neurol 2004;55 (3) 306- 319PubMedGoogle ScholarCrossref
47.
Wolk  DAPrice  JCSaxton  JA  et al.  Amyloid imaging in mild cognitive impairment subtypes [published correction appears in Ann Neurol. 2009;66(1):123].  Ann Neurol 2009;65 (5) 557- 568PubMedGoogle ScholarCrossref
48.
Jack  CR  JrLowe  VJSenjem  ML  et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.  Brain 2008;131 (pt 3) 665- 680PubMedGoogle ScholarCrossref
49.
Ewers  MBokde  AWalsh  CHampel  H Multidimensional biomarker-based diagnosis of early Alzheimer's disease.  Alzheimers Dement 2009;5 (4) P136- P137Google ScholarCrossref
50.
Jack  CR  JrLowe  VJWeigand  SD  et al. Alzheimer's Disease Neuroimaging Initiative, Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.  Brain 2009;132 (pt 5) 1355- 1365PubMedGoogle ScholarCrossref
51.
Morris  JC Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria.  Arch Neurol 2006;63 (1) 15- 16PubMedGoogle ScholarCrossref
52.
Markesbery  WRSchmitt  FAKryscio  RJDavis  DGSmith  CDWekstein  DR Neuropathologic substrate of mild cognitive impairment.  Arch Neurol 2006;63 (1) 38- 46PubMedGoogle ScholarCrossref
53.
Bennett  DASchneider  JABienias  JLEvans  DAWilson  RS Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.  Neurology 2005;64 (5) 834- 841PubMedGoogle ScholarCrossref
54.
Guillozet  ALWeintraub  SMash  DCMesulam  MM Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.  Arch Neurol 2003;60 (5) 729- 736PubMedGoogle ScholarCrossref
55.
Petersen  RCParisi  JEDickson  DW  et al.  Neuropathologic features of amnestic mild cognitive impairment.  Arch Neurol 2006;63 (5) 665- 672PubMedGoogle ScholarCrossref
56.
Jicha  GAParisi  JEDickson  DW  et al.  Neuropathological outcome of mild cognitive impairment following progression to clinical dementia.  Arch Neurol 2006;63 (5) 674- 681PubMedGoogle ScholarCrossref
57.
Feldman  HHFerris  SWinblad  B  et al.  Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study [published correction appears in Lancet Neurol. 2007;6(10):849].  Lancet Neurol 2007;6 (6) 501- 512PubMedGoogle ScholarCrossref
58.
Thal  LJFerris  SHKirby  L  et al. Rofecoxib Protocol 078 study group, A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.  Neuropsychopharmacology 2005;30 (6) 1204- 1215PubMedGoogle ScholarCrossref
59.
Winblad  BGauthier  SScinto  L  et al. GAL-INT-11/18 Study Group, Safety and efficacy of galantamine in subjects with mild cognitive impairment.  Neurology 2008;70 (22) 2024- 2035PubMedGoogle ScholarCrossref
60.
Doody  RSFerris  SHSalloway  S  et al.  Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.  Neurology 2009;72 (18) 1555- 1561PubMedGoogle ScholarCrossref
61.
Petersen  RCStevens  JCGanguli  MTangalos  EGCummings  JLDeKosky  STReport of the Quality Standards Subcommittee of the American Academy of Neurology, Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology 2001;56 (9) 1133- 1142PubMedGoogle ScholarCrossref
62.
Roberts  JS Clinical practices regarding mild cognitive impairment (MCI) among neurology service providers.  Paper presented at: International Conference on Alzheimer's Disease July 2009 Vienna, Austriahttp://www.alz.org/icad/documents/abstracts/abstracts_phaseIII_ICAD09.pdf
63.
Petersen  RCO’Brien  J Mild cognitive impairment should be considered for DSM-V.  J Geriatr Psychiatry Neurol 2006;19 (3) 147- 154PubMedGoogle ScholarCrossref
Neurological Review
December 2009

Mild Cognitive Impairment: Ten Years Later

Author Affiliations

Author Affiliations:Departments of Neurology (Drs Petersen, Knopman, and Boeve), Health Sciences Research (Drs Petersen, Roberts, and Geda), Psychiatry and Psychology (Drs Geda, Ivnik, and Smith), and Radiology (Dr Jack), Mayo Clinic College of Medicine, Rochester, Minnesota.

 

DAVID E.PLEASUREMD

Arch Neurol. 2009;66(12):1447-1455. doi:10.1001/archneurol.2009.266
Abstract

In the past 10 years, there has been a virtual explosion in the literature concerning the construct of mild cognitive impairment. The interest in this topic demonstrates the increasing emphasis on the identification of the earliest features of cognitive disorders such as Alzheimer disease and other dementias. Mild cognitive impairment represents the earliest clinical features of these conditions and, hence, has become a focus of clinical, epidemiologic, neuroimaging, biomarker, neuropathological, disease mechanism, and clinical trials research. This review summarizes the progress that has been made while also recognizing the challenges that remain.

×